Supriya Lifescience Intrinsic Value
Supriya Lifescience (SUPRIYA) median intrinsic value is ₹933.75 from 9 valuation models (range ₹242–₹1615), vs current price ₹807.25 — +15.7% upside (Trading Below Median Value), margin of safety 13.5%. Also explore SUPRIYA stock price history to track price trends across different timeframes.
SUPRIYA Valuation Methods Summary — DCF, Graham Number & P/E
Supriya Lifescience intrinsic value across 9 models vs current price ₹807.25 — upside/downside and value range per method. Browse SUPRIYA cash flow statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹506.00 | ₹404.80 - ₹607.20 | -37.3% | EPS: ₹23.00, Sector P/E: 22x |
| Book Value Method | asset | ₹1246.25 | ₹1121.62 - ₹1370.88 | +54.4% | Book Value/Share: ₹623.12, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹933.75 | ₹840.38 - ₹1027.12 | +15.7% | Revenue/Share: ₹466.88, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1614.50 | ₹1453.05 - ₹1775.95 | +100.0% | EBITDA: ₹275.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1400.78 | ₹1120.62 - ₹1680.94 | +73.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹242.17 | ₹217.95 - ₹266.39 | -70.0% | EPS Growth: 5.1%, Fair P/E: 4.1x |
| Growth Adjusted P/E | growth | ₹359.75 | ₹323.78 - ₹395.73 | -55.4% | Revenue Growth: 8.6%, Adj P/E: 15.6x |
| ROE Based Valuation | profitability | ₹1614.50 | ₹1453.05 - ₹1775.95 | +100.0% | ROE: 18.6%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹567.86 | ₹511.07 - ₹624.65 | -29.7% | EPS: ₹23.00, BVPS: ₹623.12 |
SUPRIYA Intrinsic Value vs Market Price — All Valuation Models
Supriya Lifescience fair value range ₹242–₹1615 vs current market price ₹807.25 across 9 valuation models. For current market price and key ratios, visit SUPRIYA share price.
SUPRIYA Intrinsic Value Analysis — Undervalued or Overvalued?
Supriya Lifescience median intrinsic value ₹933.75, current price ₹807.25 — Trading Below Median Value by 15.7%, margin of safety 13.5%.
What is the intrinsic value of SUPRIYA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Supriya Lifescience (SUPRIYA) is ₹933.75 (median value). With the current market price of ₹807.25, this represents a +15.7% variance from our estimated fair value.
The valuation range spans from ₹242.17 to ₹1614.50, indicating ₹242.17 - ₹1614.50.
Is SUPRIYA undervalued or overvalued?
Based on our multi-method analysis, Supriya Lifescience (SUPRIYA) appears to be trading below median value by approximately 15.7%.
SUPRIYA Financial Health — Key Ratios vs Industry Benchmarks
Supriya Lifescience financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.24 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 18.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 36.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.67x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SUPRIYA Cash Flow Quality — Operating & Free Cash Flow
Supriya Lifescience operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹165 Cr | ₹89 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹113 Cr | ₹26 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹64 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹49 Cr | ₹19 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹76 Cr | ₹53 Cr | Positive Free Cash Flow | 8/10 |